Evaluation of 10-minute post-injection 11C-PiB PET and its correlation with 18F-FDG PET in older adults who are cognitively healthy, mildly impaired, or with probable Alzheimer's disease

Advancements in dementia research, diagnostics, and care in Latin America: Highlights from the 2023 Alzheimer's Association International conference satellite symposium in Mexico City

“…Application of the ATN framework revealed that the conversion rate from MCI to dementia after 5 years of follow‐up was 85% and 50% for A+T+N+ and A−T−N+ patients, respectively 62 . Furthermore, in the first report from Brazil in a sample from Sao Paulo, 21% of controls, 36% of amnestic MCI, and 74% of AD patients had positive PIB–PET scans 65 . Despite these advances, AD diagnosis in LatAm remains primarily based on clinical information, while neuroimaging tools such as PET are limited to a few centers 64 .…”

“… 62 Furthermore, in the first report from Brazil in a sample from Sao Paulo, 21% of controls, 36% of amnestic MCI, and 74% of AD patients had positive PIB–PET scans. 65 Despite these advances, AD diagnosis in LatAm remains primarily based on clinical information, while neuroimaging tools such as PET are limited to a few centers. 64 This reinforces the importance of cross‐regional collaboration in the region to reshape the dementia diagnostic landscape in LatAm.…”

A new early warning method for mild cognitive impairment due to Alzheimer's disease based on dynamic evaluation of the “spatial executive process”

“…The current clinical screening methods with high diagnostic efficacy, such as cerebrospinal fluid screening (CSF), blood biomarker testing, positron emission computed tomography (PET), and magnetic resonance imaging (MRI), have the bottlenecks of being expensive and difficult to promote large-scale early screening in the community. 8 – 11 In addition, neuropsychological scales such as the Minimum Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA), which are widely used in AD screening, have bottlenecks of relying on doctors’ on-the-spot evaluation, intense subjectivity, time-consuming, and insufficient early warning efficacy for early-stage patients with a highly educated background. 12 – 14 Therefore, the above bottlenecks in clinical examination methods such as imaging, biology, and neuropsychological scales have led to a low diagnosis and a high underdiagnosis rate of MCI due to AD, resulting in many patients at this stage losing the best time to intervene.…”